Yeya dit Sadio Sarro
University of the Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yeya dit Sadio Sarro.
Journal of Virological Methods | 2018
James Logue; Kaylie Tuznik; Dean Follmann; Greg Grandits; Jonathan Marchand; Cavan Reilly; Yeya dit Sadio Sarro; James Pettitt; Eric Stavale; Mosoka Fallah; Gene G. Olinger; Fatorma K. Bolay; Lisa E. Hensley
As part of the scientific community’s development of medical countermeasures against Ebola virus disease, optimization of standardized assays for product evaluation is paramount. The recent outbreak heightened awareness to the scarcity of available assays and limited information on performance and reproducibility. To evaluate the immunogenicity of vaccines entering Phase I–III trials and to identify survivors, two enzyme-linked immunosorbent assays, the Filovirus Animal Non-Clinical Group assay and the Alpha Diagnostics International assay, were evaluated for detection of immunoglobulin G against Ebola virus glycoprotein. We found that the Filovirus Animal Nonclinical Group assay produced a wider range of relative antibody concentrations, higher assay precision, larger relative accuracy range, and lower regional background. Additionally, to sufficiently power a vaccine trial, use of the Filovirus Animal Nonclinical Group assay would require one third the number of participants than the Alpha Diagnostics International assay. This reduction in needed study participants will require less money, fewer man hours, and much less time to evaluate vaccine immunogenicity.
Journal of AIDS and Clinical Research | 2016
Bocar Baya; Cheick Abdel Kader Maiga; Yeya dit Sadio Sarro; Mamadou Cisse; Eleazar Dao; Sidiki Sangare; Sounkalo Dao; Souleymane Diallo
Background: The announcement of HIV-positive status is a critical moment of psycho-social destabilization that can induce changes in the behavior of an individual such a beginning or increased tobacco consumption. Objective: The objective was to study the relationship between the HIV positive status announcement and smoking behavior among people living with human immunodeficiency virus (HIV) in Bamako after the discovering their status. Methods: We did a descriptive cross-sectional study over six months from January to June 2012. Data were collected by interviewing HIV infected patients in three health care centers, departments of pulmonary diseases, department of infectious and tropical diseases and the largest HIV clinic in Mali (CESAC of Bamako). All participants have signed an informed consent before the interview. Data were analyzed using Epi-Info version 7.1.5.2 software. Results: A total of 301 HIV-infected people were included, 24% patients were current smokers 6.3% former smokers and 69.7% non-smokers. Smokers were male in majority with 93.2%. After their HIV infection status announcement, 64.9% have increased their tobacco consumption while 10.8% have decreased their consumption. Majority of patients have a good knowledge of the health risks of smoking. Of those who continue to smoke, 83.8% reported that they tried and fail to stop smoking at least one time. The main reason of their cessation was the effect on their health. And the main reason for the failure was the constant thinking of the disease. Conclusion: The announcement of the HIV positivity status must be accompanied by psychosocial support helping to overcome the emotion and stress and a smoking cessation program must be added to HIV screening program.
BMC Infectious Diseases | 2016
Bassirou Diarra; Drissa Goita; S. Tounkara; Moumine Sanogo; Bocar Baya; Antieme Combo Georges Togo; Mamoudou Maiga; Yeya dit Sadio Sarro; A. Kone; B. Kone; O. M’Baye; N. Coulibaly; Hamadoun Kassambara; Aissata B. Cissé; Michael Belson; Michael A. Polis; Jacob Otu; Florian Gehre; Martin Antonio; Sounkalo Dao; Sophia Siddiqui; Robert L. Murphy; B. C. de Jong; Souleymane Diallo
BackgroundAlthough Drug resistance tuberculosis is not a new phenomenon, Mali remains one of the “blank” countries without systematic data.MethodsBetween 2006 and 2014, we enrolled pulmonary TB patients from local TB diagnostics centers and a university referral hospital in several observational cohort studies. These consecutive patients had first line drug susceptibility testing (DST) performed on their isolates. A subset of MDR was subsequently tested for second line drug resistance.ResultsA total of 1186 mycobacterial cultures were performed on samples from 522 patients, including 1105 sputa and 81 blood samples, yielding one or more Mycobacterium tuberculosis complex (Mtbc) positive cultures for 343 patients. Phenotypic DST was performed on 337 (98.3%) unique Mtbc isolates, of which 127 (37.7%) were resistant to at least one drug, including 75 (22.3%) with multidrug resistance (MDR). The overall prevalence of MDR-TB was 3.4% among new patients and 66.3% among retreatment patients. Second line DST was available for 38 (50.7%) of MDR patients and seven (18.4%) had resistance to either fluoroquinolones or second-line injectable drugs.ConclusionThe drug resistance levels, including MDR, found in this study are relatively high, likely related to the selected referral population. While worrisome, the numbers remained stable over the study period. These findings prompt a nationwide drug resistance survey, as well as continuous surveillance of all retreatment patients, which will provide more accurate results on countrywide drug resistance rates and ensure that MDR patients access appropriate second line treatment.
Epidemiology and Infection | 2018
B. Kone; Yeya dit Sadio Sarro; Mamoudou Maiga; Moumine Sanogo; Anou M. Somboro; Bassirou Diarra; Antieme Combo Georges Togo; N. Coulibaly; B.P.P. Dembele; Drissa Goita; Bocar Baya; A. Kone; Seydou Diabaté; Michael A. Polis; Michael Belson; Sounkalo Dao; Susan Orsega; Chad J. Achenbach; Robert L. Murphy; Souleymane Diallo; Sophia Siddiqui
The global spread of non-tuberculous mycobacteria (NTM) may be due to HIV/AIDS and other environmental factors. The symptoms of NTM and tuberculosis (TB) disease are indistinguishable, but their treatments are different. Lack of research on the epidemiology of NTM infections has led to underestimation of its prevalence within TB endemic countries. This study was designed to determine the prevalence and clinical characteristics of pulmonary NTM in Bamako. A cross-sectional study which include 439 suspected cases of pulmonary TB. From 2006 to 2013 a total of 332 (76%) were confirmed to have sputum culture positive for mycobacteria. The prevalence of NTM infection was 9.3% of our study population and 12.3% of culture positive patients. The seroprevalence of HIV in NTM group was 17.1%. Patients who weighed <55 kg and had TB symptoms other than cough were also significantly more likely to have disease due to NTM as compared to those with TB disease who were significantly more likely to have cough and weigh more than 55 kg (OR 0.05 (CI 0.02-0.13) and OR 0.32 (CI 0.11-0.93) respectively). NTM disease burden in Bamako was substantial and diagnostic algorithms for pulmonary disease in TB endemic countries should consider the impact of NTM.
The International Journal of Mycobacteriology | 2017
Antieme Combo Georges Togo; Ousmane Kodio; Bassirou Diarra; Moumine Sanogo; Gagni Coulibaly; Sidy Bane; Fatimata Diallo; Anou M. Somboro; Aissata B. Cissé; Bocar Baya; Drissa Goita; Seydou Diabaté; Bourahima Kone; Yeya dit Sadio Sarro; Mamoudou Maiga; Yacouba Toloba; Michael Belson; Susan Orsega; Sounkalo Dao; Robert L. Murphy; Sophia Siddiqui; Seydou Doumbia; Souleymane Diallo
Background: To identify strains of Mycobacterium tuberculosis complex (MTBc) circulating in Bamako region during the past 10 years. Methods: From 2006 to 2016, we conducted a cross-sectional study to identify with spoligotyping, clinical isolates from tuberculosis (TB)-infected patients at different stages of their treatments in Bamako, Mali. Results: Among the 904 suspected TB patients included in the study and thereafter tested in our BSL-3 laboratory, 492 (54.4%) had MTBc and therefore underwent spoligotyping. Overall, three subspecies, i.e., MTB T1 (31.9%) and MTB LAM10 (15.3%) from lineage 4 and M. africanum 2 (16.8%) from lineage 6 were the leading causes of TB in Bamako region during the past 10 years. Other spoligotypes such as MTB T3, MTB Haarlem 2, MTB EAI3, and MTB family 33 were also commonly seen from 2010 to 2016. Conclusion: This study showed a high genetic diversity of strains isolated in Bamako region and highlights that M. tuberculosis T1 strain was the most prevalent. Furthermore, the data indicate an increasing proportion of primary drug resistance overtime in Bamako.
The International Journal of Mycobacteriology | 2016
Bassirou Diarra; Aissata B. Cissé; Ousmane Kodio; Moumine Sanogo; Bocar Baya; Antieme Combo Georges Togo; Amadou Somboro; Mohamed Tolofoudié; Boureima Degoga; Marie Laure Keita; Fatimata Diallo; Natacha Nguiakam; Gagni Coulibaly; Sidy Bane; Yeya dit Sadio Sarro; Seydou Doumbia; Robert L. Murphy; Souleymane Diallo; Bouke C. Dejong
Objective/background: The recent call for universal drug susceptibility testing (DST) for all tuberculosis (TB) patients will be difficult to meet in settings where Xpert rollout is limited, such as low prevalence of HIV and Multi-drug Resistant Tuberculosis (MDR) settings. As recommended by World Health Organization (WHO) guidelines, the success of TB treatment is measured by Ziehl–Neelsen (ZN) microscopy or auramine–rhodamine fluorescent microscopy (FM) on sputum, in which conversion to negative smear at 2 months (M) is an important predictor of treatment success, defined as a negative smear at 5M. The sputum smear that fails to convert to negative at 5M are screened for rifampicin resistance. We tested in a prospective study whether an early screen for rifampicin resistance, based on FM results at 2M, could detect MDR patients early, rather than screening all patients with GeneXpert MTB/Rif at baseline. Methods: Between February 2015 and August 2016, we enrolled new TB patients in an IRB-approved prospective cohort study at four health centers in Bamako district. Fresh sputum samples were collected at 2M and 5M to measure FM smear conversion. Patients who failed to show a decline in FM positivity at 2M (moderate or many Acid Fast Bacilli (AFB)) had their sputum tested in GeneXpert to detect rifampicin resistance. Patients who had any AFB seen at 5M were also tested using GeneXpert. Results: Of the 570 patients who were enrolled in the study, 22 (3.8%) died and 27 (4.7%) were lost to follow-up. The prevalence of HIV and TB coinfection was 12.4%, and 65.6% of the patients were male. At 2M, 32 out of 429 patients still had moderate or many AFBs in FM, and were screened by Xpert, of whom 5 (15.6%) tested rifampicin-resistant and were referred for MDR treatment. Of the 310 patients who completed 5M of treatment, 35 (11.3%) met the definition of failure (few or moderate AFB in FM) and had their sputum tested in Xpert; moreover, four (11.4%) demonstrated rifampicin resistance. In total, 67 (21.6% of 310) patients were screened by Xpert, of whom nine were detected to have MDR (or 13.4% of those screened). Conclusion: Although we cannot exclude additional MDR patients having been missed by our screening strategy, our screening algorithm at 2M detected five out of nine MDR patients. Detecting patients at 2M allowed for earlier referral, and potentially less acquired drug resistance and lower mortality. This strategy may be advantageous while awaiting further rollout of Xpert machines that will permit universal DST.
The Journal of Infectious Diseases | 2016
Bassirou Diarra; David Safronetz; Yeya dit Sadio Sarro; Amadou Kone; Moumine Sanogo; Sady Tounkara; Antieme Combo Georges Togo; Fatoumata Daou; Almoustapha Issiaka Maiga; Sounkalo Dao; Kyle Rosenke; Darryl Falzarano; Seydou Doumbia; Kathryn C. Zoon; Michael A. Polis; Sophia Siddiqui; Samba Sow; Tom G. Schwan; Heinz Feldmann; Souleyman Diallo; Ousmane A. Koita
Journal of Paediatric Laboratory Medicine | 2016
Mohamed Ag Baraïka; Aldiouma Guindo; Yeya dit Sadio Sarro; Boubacari Ali Touré; Abdoul Karim Dembélé; Ibrahima G. Traore; Mariam Kanta; Souleymane Diallo; Jean Bernard Lekana-Douki; Dapa A. Diallo
Journal of Paediatric Laboratory Medicine | 2017
Mohamed Ag Baraïka; Aldiouma Guindo; Yeya dit Sadio Sarro; Boubacari Ali Touré; Dembélé Ak; Traoré I; Kanta M; Diallo Ii S; Lekana-Douki Jb; Diallo Da
Clinical Microbiology and Infection | 2017
Moumine Sanogo; B. Kone; Bassirou Diarra; M. Maiga; Bocar Baya; Anou M. Somboro; Yeya dit Sadio Sarro; Antieme Combo Georges Togo; B.P.P. Dembele; Drissa Goita; A. Kone; O. M'Baye; N. Coulibaly; Seydou Diabaté; Bréhima Traoré; Mh Diallo; Y.I. Coulibaly; Paul Saleeb; Michael Belson; Susan Orsega; Sophia Siddiqui; Michael A. Polis; Sounkalo Dao; Robert L. Murphy; Souleymane Diallo